Last Updated : March 22, 2024
Details
FilesGeneric Name:
Saxagliptin
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Bristol-Myers Squibb / AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Onglyza
Project Line:
Reimbursement Review
Project Number:
SR0329-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Not applicable - Predated performance metrics
Submission Type:
Initial
Indications:
Diabetes mellitus (Type 2)
Recommendation Type:
List with criteria/condition
Final Recommendation:
Files
Last Updated : March 22, 2024